Daniel MacDonald

Dive into the evolving landscape of National Pharmacare and its implications for nationwide efforts towards achieving affordable, equitable access to medications across Canada. Source your plan of action with insights on:

• National Pharmacare aiming to unify drug coverage, reduce disparities, and improve affordability for all Canadians.
• Key challenges involving balancing cost-containment with innovation and aligning federal-provincial priorities.
• Stakeholder collaboration from payers to patients being essential for sustainable and equitable access models.

Achieve a comprehensive understanding of the national pharmacare debate and how to prepare for future policy to navigate evolving healthcare landscapes and drive equitable access to medications across Canada.

The federal government has committed $1.5 billion over three years to help provinces and territories cover the costs of high-priced rare disease treatments. Implementing the National Strategy for Drugs for Rare Diseases requires ongoing collaboration, transparency, and adaptability among all stakeholders. Walk away with an action plan on:

• Understanding the challenges still faced by patients across Canada on receiving access to the right treatments.
• Assessing the steps towards collaboration made in 2025 at the provincial, federal, and industry level.
• Exploring how this funding has reduced treatment delays, improved patient outcomes, and fostered a more sustainable rare disease drug ecosystem.

Improve coordination of access to treatments for rare disease patients to ensure timely, equitable access to life-saving therapies and enhance overall patient outcomes.